抗胆固醇负担对轻度行为障碍发展的影响
Clio E Franklin1,2, Paul B Rosenberg1, Constantine G Lyketsos1
1Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 600 N Wolfe St, Baltimore, Maryland, 21287, USA.
medRxiv : the preprint server for health sciences
|December 18, 2025
概括
较高的抗胆固醇负担 (ACB) 与老年人患轻度行为障碍 (MBI) 的风险增加有关. 这凸显了在处方抗胆固醇药物时需要谨慎,因为潜在的MBI风险.
科学领域:
- 老年学是指老年学的学科.
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 轻度行为障碍 (MBI) 是一种综合症,其特点是生命晚期出现神经精神症状.
- 抗胆固醇药物经常被处方给老年人.
- 无论是MBI还是抗胆固醇药物暴露,都与痴呆的风险增加有关.
研究的目的:
- 调查抗胆固醇负担 (ACB) 与老年人发生MBI的风险之间的关联.
- 量化累积抗胆固醇暴露与MBI发展之间的关系.
主要方法:
- 利用了国家阿尔茨海默氏症协调中心的数据库,包括认知不受损的个人.
- 定义的MBI状态使用算法映射神经精神病库存问卷评级到MBI检查清单 (MBI-C).
- 评估了随时间变化的ACB分数与事件MBI风险之间的联系,平均随访时间为5.64年.
主要成果:
- 总共分析了4865名参与者.
- 较高的最大ACB得分与患MBI的可能性增加显著相关 (p<0.001).
- 随时间变化的ACB得分显示出与发生的MBI (HR 1.12,95% CI 1.05-1.19,p<0.001) 有显著的关联,即使对死亡风险进行了调整.
结论:
- 抗胆固醇负担是老年人发展轻度行为障碍的重要危险因素.
- 临床医生应仔细考虑MBI的潜在风险,在给这种人群开处方抗胆固醇药物时.
相关概念视频
Attention-Deficit/Hyperactivity Disorder
717
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
717
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.4K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.4K
Parkinson's Disease: Treatment
940
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
940
Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752
Cholinergic Antagonists: Pharmacological Actions
1.6K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.6K
Cholinergic Antagonists: Therapeutic Uses
1.3K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.3K


